Bank of New York Mellon Corp Decreases Stock Holdings in PDS Biotechnology Co. (NASDAQ:PDSB)

Bank of New York Mellon Corp reduced its position in shares of PDS Biotechnology Co. (NASDAQ:PDSB) by 70.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,295 shares of the company’s stock after selling 69,555 shares during the period. Bank of New York Mellon Corp owned about 0.08% of PDS Biotechnology worth $86,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in PDSB. Kathleen S. Wright Associates Inc. bought a new position in shares of PDS Biotechnology during the 1st quarter valued at about $28,000. Tempus Wealth Planning LLC bought a new position in shares of PDS Biotechnology in the second quarter valued at approximately $55,000. Inspirion Wealth Advisors LLC raised its position in shares of PDS Biotechnology by 1.4% in the second quarter. Inspirion Wealth Advisors LLC now owns 359,894 shares of the company’s stock valued at $1,054,000 after purchasing an additional 4,917 shares during the period. Finally, Vanguard Group Inc. increased its position in PDS Biotechnology by 5.5% during the first quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock worth $6,288,000 after acquiring an additional 82,135 shares during the period. 26.84% of the stock is owned by institutional investors and hedge funds.

PDS Biotechnology Price Performance

Shares of PDS Biotechnology stock opened at $3.37 on Friday. The company has a current ratio of 3.84, a quick ratio of 3.84 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $123.61 million, a PE ratio of -2.48 and a beta of 1.88. The business’s 50-day moving average price is $3.25 and its 200-day moving average price is $3.38. PDS Biotechnology Co. has a 12 month low of $2.53 and a 12 month high of $6.85.

PDS Biotechnology (NASDAQ:PDSB) last released its earnings results on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.08. During the same period in the previous year, the firm posted ($0.37) earnings per share. Sell-side analysts forecast that PDS Biotechnology Co. will post -1.3 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on PDSB shares. B. Riley reduced their target price on shares of PDS Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday, June 12th. Alliance Global Partners raised PDS Biotechnology to a “strong-buy” rating in a research note on Wednesday, August 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $21.00 price target on shares of PDS Biotechnology in a research report on Tuesday, September 17th. One analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $14.25.

PDS Biotechnology Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.